Intentions on CLH proposals provide information to ECHA and to the stakeholders about planned CLH dossiers. Dossier submitters are therefore encouraged to provide to ECHA an intention as early as possible in the preparation of the CLH dossier. Intentions are published in the Registry of Intentions (RoI) on ECHA's website to inform all interested parties about the CLH dossiers that are under preparation and to avoid situations where two or more dossiers are prepared for the same substance at the same time.
If the submitter of an intention agrees, their contact details may be published with the intention, allowing other parties to provide any relevant information on the particular substance and the hazard classes concerned directly to the prospective dossier submitter.
Member State Competent Authorities (MSCAs) may propose a new harmonised classification and labelling for any substance that is within the scope of the CLP Regulation or a revision of an existing harmonised classification and labelling for a substance.
Any Manufacturer, Importer or Downstream user (M, I or DU) may propose a new harmonised classification and labelling for substances which are not active substances for biocidal products or plant protection products
Where the CLH proposal of the manufacturer, importer or downstream user concerns the harmonised classification and labelling of a substance in accordance with Article 37(3) CLP, it shall be accompanied by the fee determined by the Commission in accordance with the Commission Regulation (EU) No 440/2010.
The dossier submitters aiming to prepare a CLH dossier are encouraged to contact ECHA to discuss any issues that concern, for example, substance identity, hazard class assessment, robust study summaries, or the CLH report template. For support, please contact the ECHA Secretariat at email@example.com.
The Committee for Risk Assessment needs to adopt an opinion on a CLH proposal within 18 months from the receipt of the proposal by the Agency. This deadline applies once the proposal fulfils the criteria set out in the CLP Regulation. Should a fee apply for proposals submitted by manufacturers, importers or downstream users, the start of the 18-month deadline will be the date when this fee is received by the Agency.
A submission via the corresponding webform is required for any initiation or update of an activity undertaken by an Authority or Industry. This allows ECHA to manage the activity in an efficient manner and to inform other authorities and stakeholders via the Activity Coordination Table (ACT) or its public version (PACT) with up to date information on the activity undertaken.
Fields marked with * are required. Other information is only required if changed from previous submissions on the same external identifier.
Specify the organisation who is responsible for performing this activity. In case, activities on this substance are performed by more than one Member State Authority (e.g. Substance Evaluation performed by one authority and PBT assessment by another one), please tick the box indicating that this is a "Shared substance".
On the website, only information agreed to be disclosed for this activity will be displayed. Nevertheless, it is advisable to provide more specific contact information (contact person, email) to ECHA in order to facilitate the communication between the organisation notifying an activity, other authorities and ECHA. This information will be kept internally in ECHA which will be in charge of facilitating communication and exchanges.
Please note: If you are a Manufacturer, Importer or Downstream user (M, I or DU), please create your account in REACH-IT (if you do not have one already) before proceeding with the submission of the webform.
Information to be used on the ECHA website or formal communication when relevant.
Information for internal ECHA use
I declare that I am an authorised representative of an MSCA, or a manufacturer, importer or downstream User of a substance established in any of the Member States under the conditions laid down in Article 37 of the Regulation (EC) No 1272/2008 (CLP Regulation).
In cases foreseen under Article 37(2) of the CLP Regulation, I declare that I am an authorised representative of the legal entity for the purpose of submitting an intention for the CLH dossier that is currently planned/under preparation, or to submit the CLH proposal, and I am authorised to transmit and receive documents on behalf of this legal entity. I am aware that a power of attorney may be asked by the Agency.
As a submitter, I understand that it is my responsibility to verify the data entered in my REACH-IT account and to provide for the accessibility and functionality of my email address in order to ensure the communication with ECHA.
As a manufacturer, importer or downstream user or as a party representing a manufacturer, importer or downstream user I also understand that the declaration of the company size in my REACH-IT account is to be based on the standards stipulated in the Annex to Commission Recommendation 2003/361/EC concerning the definition of micro, small and medium-sized enterprises, and that the calculation of the relevant headcount and financial figures particularly includes the relevant data of partner and linked enterprises as defined in the Recommendation. As a representative on behalf of a manufacturer, importer or downstream user, I understand that the company size shall be the size of the manufacturer, importer or downstream user that I represent.
As a submitter I confirm the correctness and completeness of the data supplied through this webform.
By submitting any information through the webform I guarantee to hold all necessary rights with regard to the information provided, including but not limited to copyright where applicable, and therefore that I am entitled to submit the said information for the purposes listed herein and for its use by ECHA, including its Committees.
A CLH dossier can be prepared for a substance with a well-defined composition (mono-constituent, multi-constituent) or a substance of Unknown or Variable composition, Complex reaction products or Biological materials (UVCB).
A CLH dossier can also be prepared for a group of substances (e.g. close structural analogues or various salts of the same substance). In the event that you are aiming to prepare a CLH proposal covering several substances, please contact the ECHA Secretariat (firstname.lastname@example.org) before you start drafting a proposal.
More information regarding the preparation of a CLH dossier is available on the ECHA website at the following links
Note that fields marked with (*) are obligatory. If the information is not relevant, not available or unknown please record this accordingly.
Please indicate for the substance the following information (for multi-constituent substances and UVCBs please identify the different constituents and their concentration):
Please specify here other constituents of multi-constituent substances including their concentrations ranges. For UVCBs, please provide all known constituents and their concentration ranges. Impurities and transformation products that are relevant for classification and labelling should also be reported in all cases. Fill in one substance identity for each constituent/impurity/transformation product.
Please note that if an access to documents application pursuant to Regulation (EC) No 1049/2001 on public access to documents is received regarding this information, in order to define its position ECHA will have to first perform an assessment of the content of this information. Therefore, you are invited to indicate below any reason for which disclosure of this information should be denied. Please note that ECHA can only examine reasons appearing in Article 4 of the Regulation (EC) No 1049/2001 on public access to documents as valid.
I have the following reasons enumerated in Article 4(1) or 4(2) of Regulation (EC) No 1049/2001 regarding public access to documents why the information submitted as confidential cannot be disclosed to persons requesting access to documents (please explain below in the commenting field those reasons; a reason could be that the protection of your commercial interests, including intellectual property, would be undermined)."